ADVERTISEMENT

finance

Atai Life Sciences NV (NASDAQ:ATAI) up 10%; Individual investors, who own 59% of the shares, benefited along with institutions

ADVERTISEMENT

A look at the shareholders of Atai Life Sciences NV (NASDAQ:ATAI) can tell us which group is the most powerful. And the group that has the largest share of the pie is individual investors with 59% ownership. That is, the group has the most to gain if the stock rises (or the most to lose if it falls).

While individual investors were the group that gained the most after last week’s price increase of 10%, institutions also received a 24% discount.

Let’s take a closer look to see what the different types of shareholders can tell us about Atai Life Sciences.

Check out our latest analysis for Atai Life Sciences

loss of property

What does institutional ownership tell us about Atai Life Sciences?

Institutions usually measure themselves against a benchmark when they report to their own investors, so they often become more optimistic about a stock once it’s included in a major index. We would expect most companies to keep an institution on the registry, especially as they grow.

We see that Atai Life Sciences has institutional investors; And they own a fair share of the company’s stock. This suggests some credibility with professional investors. But we cannot just rely on that, because institutions sometimes make bad investments, just like everyone else. If two large institutional investors try to sell a share at the same time, it is not uncommon for the share price to fall sharply. So it’s worth looking at Atai Life Sciences’ past earnings trajectory (below). Of course, keep in mind that there are other factors to consider as well.

Also read  Growing concerns about tenants being abused by corporate investors

profit and sales growth

The hedge fund does not hold many shares in Atai Life Sciences. Apeiron Investment Group Limited is currently the largest shareholder with 17% of the outstanding shares. The second and third largest shareholders hold 6.5% and 3.7% of the outstanding shares respectively.

A closer look at our ownership figures shows that the top 25 shareholders collectively own less than half of the register, indicating a large group of small shareholders with no single shareholder holding a controlling interest.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiment to know which way the wind is blowing. There are plenty of analysts following the stock, so it might be worth taking a look to see what they’re predicting.

Insider property of Atai Life Sciences

The definition of a company’s insider can be subjective and varies by jurisdiction. Our data reflects individual insiders, at least board members. The company’s management runs the company, but the CEO will be accountable to the board, even if he is a member of it.

Insider ownership is positive when it indicates that leadership thinks like the true owners of the company. However, a high share of insiders can also give excessive power to a small group within the company. It can be negative in some circumstances.

Our most recent data indicates that insiders own less than 1% of Atai Life Sciences NV. It appears board members own no more than $1.9 million in stock in the $526 million company. Many investors prefer to see the board invest more in smaller companies. You can click here to see if those insiders are buying or selling.

Also read  Tanzania YC alumnus Ramani raises $32 million to digitize CPG supply chains and lend to resellers

general public property

The general public, mostly individual investors, hold a 59% stake in Atai Life Sciences, suggesting that it is quite a popular stock. This level of ownership gives investors the power to make certain important policy decisions beyond the wider public, such as board composition, executive compensation, and dividend payout ratios.

private property

Private equity firms hold a 17% stake in Atai Life Sciences. This suggests that they can influence important policy decisions. Some investors may be encouraged by this, as private equity can sometimes drive strategies that help the market see value in the company. Alternatively, those holders can exit the investment after it is made public.

Next steps:

It is always wise to think about the different groups that can own shares in a company. But to better understand Atai Life Sciences, we need to consider many other factors. Take the risk by leading by example – Atai Life Sciences 3 warning signs (and 1 that can’t be ignored) We think you should be aware of this.

If you’re like me, you might want to wonder if this business will grow or shrink. Fortunately, you can check out this free report with analyst forecasts for the future.

NB: the figures in this article have been calculated on the basis of data for the last twelve months, which means the period of 12 months ending on the last day of the month in which the annual accounts were drawn up. This may not correspond to the figures in the annual report for the full year.

Also read  NFP acquires Tailored Finance Limited, health and life insurance advisers in Dublin: NFP Corp

Do you have feedback on this article? Concerned about the content? stay in touch directly with us. You can also send an email to the editorial team(at)simplywallst.com.

This Simply Wall St article is general in nature. We only comment based on historical data and analyst forecasts using an unbiased methodology and our articles are not intended to provide financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or your financial situation. We strive to provide you with long-term focused analytics driven by fundamental data. Please note that our analysis may not take into account the latest price sensitive company announcements or quality material. Simply Wall Street has no position in any of the listed stocks.

Join a paid user research session
You will receive a $30 Amazon Gift Card for 1 hour of your time while you help us develop better investment tools for individual investors like you. Register here

Source

ADVERTISEMENT

ADVERTISEMENT

Leave a Comment